Results 41 to 50 of about 1,265,475 (213)

Cannabichromene is a cannabinoid CB ₂ receptor agonist [PDF]

British Journal of Pharmacology, 2018
Background and Purpose Cannabichromene (CBC) is one of the most abundant phytocannabinoids in Cannabis spp . It has modest antinociceptive and anti‐inflammatory effects and potentiates some effects of Δ 9
Udoh, Michael, Santiago, Marina, Devenish, Steven, McGregor, Iain S., Connor, Mark   +4 more
openaire   +2 more sources

Cannabinoids: A New Group of Agonists of PPARs

PPAR Research, 2007
Cannabinoids have been used medicinally and recreationally for thousands of years and their effects were proposed to occur mainly via activation of the G-protein-coupled receptor CB1/CB2 (cannabinoid receptor 1/2).
Yan Sun, Andy Bennett
doaj   +1 more source

Indomethacin plus minocycline coadministration relieves chemotherapy and antiretroviral drug-induced neuropathic pain in a cannabinoid receptors-dependent manner

Journal of Pharmacological Sciences, 2019
Neuropathic pain sometimes occurs during chemotherapy with paclitaxel or HIV/AIDS antiretroviral therapy with nucleoside reverse transcriptase inhibitors (NRTIs).
Willias Masocha, Amal Thomas
doaj   +1 more source

SR144528 as Inverse Agonist of CB2 Cannabinoid Receptor

Journal of Veterinary Science, 2002
It is now well established that several G protein- coupled receptors can signal without agonist stimulation (constitutive receptors). Inverse agonists have been shown to inhibit the activity of such constitutive G protein-coupled receptor signaling. Agonist activation of the G(i/o)-coupled peripheral cannabinoid receptor CB2 normally inhibits adenylyl ...
Man-Hee, Rhee, Sang-Keun, Kim
openaire   +2 more sources

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor

Pharmacology Research & Perspectives, 2023
The rapid structural evolution and emergence of novel synthetic cannabinoid receptor agonists (SCRAs) in the recreational market remains a key public health concern.
Monica Patel, Natasha L. Grimsey, Samuel D. Banister, David B. Finlay, Michelle Glass   +4 more
doaj   +1 more source

Neurotransmitter‐Defined Degeneration Patterns in Sporadic and C9orf72‐Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems—Implications for Therapy Development

Annals of Neurology, EarlyView.
Objective Amyotrophic lateral sclerosis (ALS) has a markedly distinctive clinical and neuroradiological signature, with the preferential involvement of specific brain networks and the apparent sparing of others. The molecular underpinnings of the strikingly selective anatomical vulnerability have not been fully elucidated to date despite the potential ...
Marlene Tahedl, We Fong Siah, Jasmin Lope, Jennifer C. Hengeveld, Mark A. Doherty, Russell L. McLaughlin, Orla Hardiman, Ee Ling Tan, Alison Toomey, Jana Kleinerova, Peter Bede   +10 more
wiley   +1 more source

Cannabinoid receptors distribution in mouse cortical plasma membrane compartments

Molecular Brain, 2021
The type 1 and type 2 cannabinoid receptors (CB1 and CB2 receptors) are class A G protein-coupled receptors (GPCRs) that are activated by endogenous lipids called endocannabinoids to modulate neuronal excitability and synaptic transmission in neurons ...
Hajar Miranzadeh Mahabadi, Haseeb Bhatti, Robert B. Laprairie, Changiz Taghibiglou   +3 more
doaj   +1 more source

Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors [PDF]

British Journal of Pharmacology, 2013
Background and PurposeAlthough cannabinoid CB2 receptor ligands have been widely characterized in recombinant systems in vitro, little pharmacological characterization has been performed in tissues natively expressing CB2 receptors. The aim of this study was to compare the pharmacology of CB2 receptor ligands in tissue natively expressing CB2 receptors
Pietro, Marini, Maria-Grazia, Cascio, Angela, King, Roger G, Pertwee, Ruth A, Ross   +4 more
openaire   +2 more sources

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Purification and characterization of heterologously produced cannabinoid receptor 1 and G proteins [PDF]

, 2007
G protein coupled receptors form the largest group of transmembrane proteins, which are involved in signal transduction and are targeted directly or indirectly by 40-50% of the drugs in the market.
Chillakuri, Chandramouli, Chillakuri, C.
core